Health
Lilly to Test Zepbound in Psoriasis to Follow Up on Weight-Loss Success
- Blockbuster Zepbound has anti-inflammatory properties
- Findings in diabetes prevention lift shares to record high
Eli Lilly & Co. is running large studies of Zepbound in related health conditions like sleep apnea and heart failure, and similar studies with its next-generation drugs.
Photographer: Shelby Knowles/BloombergThis article is for subscribers only.
Eli Lilly & Co. is using its runaway success in obesity as a bridge into another lucrative area of medicine: immunology.
This fall, the company will begin recruiting for trials to test its popular weight-loss shot Zepbound with psoriasis drug Taltz to see if the combination boosts effectiveness, Chief Scientific Officer Daniel Skovronsky said. The Indianapolis-based drugmaker is also exploring combination studies with Zepbound in inflammatory bowel disease, another immune disorder.